SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Sarepta Therapeutics (Formerly known as AVI BioPharma, Inc.) Enters Into Collaboration for the Development of Additional Exon-Skipping Product for Duchenne Muscular Dystrophy